Navigation Links
ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study

ther development of ecabet sodium (including but not limited to statements that ISTA will complete its analysis and confirm its preliminary Phase IIb findings, meet with the FDA, and initiate a Phase III study with respect to ecabet sodium during 2008), the potential of ecabet sodium to treat dry eye syndrome and its potential advantages over other currently marketed dry eye products, ISTA's statements about potential future objective endpoints for Phase III studies and ISTA's goals of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S. are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. Such statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the risk that full analysis of the Phase IIb data or further testing of ecabet sodium, will not reflect the preliminary Phase IIb results, or support any or all of the conclusions provided in this press release; delays, risks and uncertainties related to ISTA's ecabet sodium development program (including the difficulty of predicting the timing or outcome of ISTA's product development efforts and the FDA or other governmental agency approval or actions); uncertainties and risks regarding market acceptance of ISTA's approved products and the impact of competitive products and pricing; risks and uncertainties related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products, and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property r
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 1 Older adults can improve memory and attention ... presented today at the annual meeting of the American Geriatrics ... study and a professor at the University of Southern ... gains persist months after the training ended.A total of 487 ...
... April 30 SpectraScience, Inc. (OTC Bulletin Board: SCIE) ... Iowa,s Des Moines Register published an article reporting that its LUMA ... the University of Iowa . Since Last July, researchers ... have used the LUMA Cervical Imaging System in more ...
Cached Medicine Technology:Brain Training Improves Memory and Attention and the Effects Last 2Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 2Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 3
(Date:12/19/2014)... 2014 Today, Balfleet.com , a ... announces its formal dress promotion. All the old and ... 60% off. , Balfleet.com is well-known for its high ... prom dresses, cocktail dresses and more. Its formal dresses ... guarantee, and they can create an elegant look when ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... OK (PRWEB) December 19, 2014 Eufaula, ... home to Lake Eufaula, the state’s largest lake with ... lakeside town is home to a little more than ... 1:00 P.M. on Saturday, the 6th of December. , ... its way through downtown Eufaula on Main Street. ...
(Date:12/19/2014)... December 20, 2014 The print component ... and Business subscription of the Toronto Star, with a ... of 622,169. The digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... . , The publication features an exclusive interview ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Potentially illness-causing E. coli bacteria ... farmers markets, according to a new study. Researchers ... from 13 farmers markets in Los Angeles and Orange ... of almost 150 samples tested, 24 percent were positive ... according to the researchers. Both types of bacteria ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... their opinion- Nature’s way is far superior to pre-planned caesarian ... of it being unnecessary. , According to their ... encountered by a woman who opts for a C-section, in ... higher than that of a woman undergoing natural delivery. ...
... Researchers at UT Southwestern Medical Center have found that ... ,"We have discovered that C-Reactive Protein (CRP) ... hypertension, it actually induces hypertension," said Dr. Wanpen Vongpatanasin, ... the study appearing in the February issue of Circulation. ...
... PhD, published the first results showing that a biological phenomenon ... Since then he has used RNAi gene therapy to effectively ... mice. ,With three human RNAi gene therapy trials ... in RSV pneumonia - the technique Kay pioneered may be ...
... By first probing the way primitive yeast make ... long-sought protein whose human// counterpart controls cholesterol production ... study by investigators at Johns Hopkins University School ... Lilly Co., was published in the February issue ...
... Diabetes case management that takes a patient’s specific ... and decrease the incidence of diabetes-related complications over ... ,"Better management results in reduced long-term complications, ... said lead researcher Todd Gilmer, Ph.D. ...
... Jumping on a garden trampoline is a fun form of ... for children and youths// than traffic, according to a new ... of concern "especially due to neck and head injuries" that ... northern Sweden told the Svenska Dagbladet newspaper. ,The ...
Cached Medicine News:Health News:C-Reactive Protein Induces Hypertension 2Health News:RNAi Shows Promise in Gene Therapy 2Health News:Primitive Yeast Yields Secrets Of Human Cholesterol And Drug Metabolism 2Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
The ACMI™ Operative Laparoscopy System is designed for single- and dual-incision CO2 laser procedures and is used with 45cm laparoscopic instruments....
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Stryker bariatric laparoscopes set the standard in picture quality....
Medicine Products: